Physician profile
Mark Dewey Andersen
NPI 1972525251
$5,819.75
in general payments reported to CMS, 2019-2025
37 companies · $1,011 in 2025
The $1,011 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,039 · 2020: $541 · 2021: $663 · 2022: $844 · 2023: $915 · 2024: $807 · 2025: $1,011.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,733.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,733.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,103.17 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Lilly USA, LLC | $917.63 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $902.41 | 2019-2025 | Airsupra, Farxiga, Pulmicort |
| Amgen INC. | $597.80 | 2019-2025 | Evenity, Prolia |
| Novo Nordisk INC | $493.32 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $307.83 | 2019-2025 | |
| Astellas Pharma US INC | $189.62 | 2021-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $179.64 | 2019-2024 | Tradjenta, Jardiance, Synjardy |
| Janssen Pharmaceuticals, INC | $138.47 | 2019-2023 | Invega Sustenna |
| Novartis Pharmaceuticals Corporation | $136.35 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $120.38 | 2022-2024 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $91.88 | 2021-2025 | |
| Abbott Laboratories | $68.38 | 2019-2025 | Freestyle Libre 3 |
| Biohaven Pharmaceuticals, INC. | $58.59 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.60 | 2019-2023 | Xifaxan |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $50.10 | 2022-2023 | Ajovy |
| Sanofi-Aventis U.S. LLC | $38.88 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $38.02 | 2025 | Gemtesa |
| Genentech USA, INC. | $31.57 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.21 | 2021 | |
| Allergan, INC. | $27.70 | 2020 | |
| Seqirus USA INC | $20.82 | 2024 | Flucelvax |
| Biohaven Pharmaceutical Holding Company LTD. | $18.69 | 2022 | |
| Xeris Pharmaceuticals, INC. | $18.18 | 2023 | Gvoke Hypopen |
| Idorsia Pharmaceuticals US INC | $17.40 | 2023 | Quviviq |
| Organon LLC | $15.73 | 2022 | |
| Amarin Pharma, INC. | $15.65 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $15.14 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $14.35 | 2021 | |
| Boston Scientific Corporation | $14.21 | 2021 | |
| Ethicon US, LLC | $14.12 | 2022 | |
| Shire North American Group INC | $14.00 | 2019 | |
| Esperion Therapeutics, INC. | $13.75 | 2020 | |
| Genzyme Corporation | $13.57 | 2021 | |
| Merck Sharp & Dohme LLC | $12.82 | 2023 | Pneumovax 23, Vaxneuvance, Gardasil 9 |
| Gilead Sciences, INC. | $12.75 | 2023 | |
| Eisai INC. | $12.02 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Andersen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.